Bank of America’s aTyr Pharma ATYR Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $237K | Buy |
303,559
+176,859
| +140% | +$149K | ﹤0.01% | 5269 |
|
|
2025
Q4 | $99.2K | Sell |
126,700
-50,971
| -29% | -$41.8K | ﹤0.01% | 5628 |
|
|
2025
Q3 | $128K | Buy |
177,671
+135,325
| +320% | +$613K | ﹤0.01% | 6487 |
|
|
2025
Q2 | $215K | Sell |
42,346
-245,965
| -85% | -$968K | ﹤0.01% | 6150 |
|
|
2025
Q1 | $871K | Buy |
288,311
+197,087
| +216% | +$719K | ﹤0.01% | 5324 |
|
|
2024
Q4 | $330K | Buy |
91,224
+90,604
| +14,614% | +$274K | ﹤0.01% | 5827 |
|
|
2024
Q3 | $1.09K | Sell |
620
-116,417
| -99% | -$212K | ﹤0.01% | 7228 |
|
|
2024
Q2 | $183K | Sell |
117,037
-39,138
| -25% | -$68.1K | ﹤0.01% | 5933 |
|
|
2024
Q1 | $305K | Buy |
156,175
+7,416
| +5% | +$12.9K | ﹤0.01% | 5647 |
|
|
2023
Q4 | $210K | Buy |
148,759
+148,643
| +128,141% | +$191K | ﹤0.01% | 6042 |
|
|
2023
Q3 | $183 | Sell |
116
-1,367
| -92% | -$2.53K | ﹤0.01% | 7417 |
|
|
2023
Q2 | $3.2K | Buy |
+1,483
| New | +$3.24K | ﹤0.01% | 7071 |
|
|
2023
Q1 | – | Sell |
-64
| Closed | -$140 | – | 8338 |
|
|
2022
Q4 | $140 | Buy |
+64
| New | +$151 | ﹤0.01% | 7616 |
|
|
2021
Q4 | – | Sell |
-382
| Closed | -$3K | – | 8711 |
|
|
2021
Q3 | $3K | Buy |
382
+82
| +27% | +$491 | ﹤0.01% | 7847 |
|
|
2021
Q2 | $1K | Buy |
300
+260
| +650% | +$1.11K | ﹤0.01% | 7657 |
|
|
2021
Q1 | $0 | Buy |
+40
| New | +$188 | ﹤0.01% | 7847 |
|
|
2020
Q2 | – | Sell |
-1,098
| Closed | -$3K | – | 7170 |
|
|
2020
Q1 | $3K | Buy |
+1,098
| New | +$4.74K | ﹤0.01% | 6591 |
|
|
2019
Q4 | – | Sell |
-36
| Closed | – | – | 7467 |
|
|
2019
Q3 | $0 | Sell |
36
-714
| -95% | -$2.63K | ﹤0.01% | 7552 |
|
|
2019
Q2 | $4K | Buy |
750
+201
| +37% | +$1.36K | ﹤0.01% | 6878 |
|
|
2019
Q1 | $4K | Hold |
549
| – | – | ﹤0.01% | 6837 |
|
|
2018
Q4 | $4K | Hold |
549
| – | – | ﹤0.01% | 6804 |
|
|
2018
Q3 | $6K | Sell |
549
-2,257
| -80% | -$24.7K | ﹤0.01% | 6791 |
|
|
2018
Q2 | $36K | Sell |
2,806
-182
| -6% | -$4.32K | ﹤0.01% | 6300 |
|
|
2018
Q1 | $111K | Hold |
2,988
| – | – | ﹤0.01% | 5688 |
|
|
2017
Q4 | $146K | Sell |
2,988
-279
| -9% | -$17.2K | ﹤0.01% | 5567 |
|
|
2017
Q3 | $231K | Sell |
3,267
-100
| -3% | -$4.63K | ﹤0.01% | 5316 |
|
|
2017
Q2 | $160K | Sell |
3,367
-41
| -1% | -$1.92K | ﹤0.01% | 5402 |
|
|
2017
Q1 | $167K | Sell |
3,408
-291
| -8% | -$13.3K | ﹤0.01% | 5395 |
|
|
2016
Q4 | $111K | Buy |
3,699
+7
| +0.2% | +$287 | ﹤0.01% | 5577 |
|
|
2016
Q3 | $164K | Sell |
3,692
-475
| -11% | -$20.5K | ﹤0.01% | 5224 |
|
|
2016
Q2 | $162K | Buy |
+4,167
| New | +$194K | ﹤0.01% | 5314 |
|
|
2016
Q1 | – | Sell |
-282
| Closed | -$39K | – | 7372 |
|
|
2015
Q4 | $39K | Buy |
282
+281
| +28,100% | +$40K | ﹤0.01% | 6159 |
|
|
2015
Q3 | $0 | Sell |
1
-11
| -92% | -$2.51K | ﹤0.01% | 7438 |
|
|
2015
Q2 | $3K | Buy |
+12
| New | +$3.73K | ﹤0.01% | 6981 |
|
Other funds holding ATYR
VCM
GCP
Bank of America's ATYR Position: Q1 2026 in Review
Bank of America increased its aTyr Pharma (ATYR) stake by 140% in Q1 2026, buying an estimated $149K and bringing the position to 303,559 shares worth $237K. The position accounts for ﹤0.01% of the portfolio, ranked #5269.
Bank of America first reported a position in ATYR in Q2 2015 and has held it in 34 quarters since. The position peaked at $871K in Q1 2025. 111 funds tracked by Wall St. Rank hold ATYR as of Q1 2026.
- Bank of America held 303,559 shares of aTyr Pharma worth $237K as of Q1 2026.
- Bank of America bought 176,859 aTyr Pharma shares in Q1 2026, an estimated $149K.
- aTyr Pharma made up ﹤0.01% of Bank of America's portfolio in Q1 2026, its #5269 holding.
- Bank of America first reported a position in aTyr Pharma in Q2 2015 and has held it in 34 quarters since.
- Bank of America's aTyr Pharma position peaked at $871K in Q1 2025.
- 111 funds tracked by Wall St. Rank held aTyr Pharma as of Q1 2026.
Based on Bank of America's 13F filing for Q1 2026, filed 18 May 2026.